US Patent

US11638692 — Composition and method for vancomycin oral liquid

Formulation · Assigned to Azurity Pharmaceuticals Inc · Expires 2035-03-13 · 9y remaining

Vulnerability score 50/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a stable vancomycin hydrochloride powder for oral liquid formulations and methods for using those formulations to treat certain diseases.

USPTO Abstract

The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.

Drugs covered by this patent

Patent Metadata

Patent number
US11638692
Jurisdiction
US
Classification
Formulation
Expires
2035-03-13
Drug substance claim
No
Drug product claim
Yes
Assignee
Azurity Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.